Circio Holding ASA is calling for an EGM on 27 September 2023 to vote on the
following items:

 1. The amendment to the Investment Agreement with Atlas
 2. A 30:1 reverse stock split to increase the trading price to above NOK 1
(with necessary capital increase)
 3. A reduction of the share capital of 2.5 NOK per share

Reference is made to the announcement by Circio Holding ASA on 24 August 2023
that certain changes to the Investment Agreement with Atlas Special
Opportunities, LLC ("Atlas") will be presented for a shareholder vote in an
extraordinary general meeting (EGM) during September 2023. Due to difficult
market conditions and reduced trading volume in Circio shares it has been
challenging to utilize the financing facility as foreseen, and risk has
increased for both Circio and Atlas. An amendment to the Investment Agreement
relating to trading limitations and fees has been negotiated and agreed with
Atlas, which the board and management of Circio recommend for shareholders to
approve to ensure necessary flexibility for both parties to effectively manage
the financing structure.

Further, to comply with minimum share price obligations for companies listed on
the Oslo Stock Exchange, pursuant to which the market value for listed shares
shall not be lower than NOK 1 for a period of longer than six months, the board
of directors proposes that the Circio Holding ASA shares are consolidated in the
ratio of 30:1 (reverse split), whereby 30 existing shares, each with a nominal
value of NOK 0.1, shall be consolidated to one share with nominal value NOK 3.
Following the share consolidation, it is proposed that the Company's share
capital shall be reduced by NOK 2.5 to NOK 0.5 per share, and that the reduction
amount is used to cover a portion of the Company's accumulated losses, as
reflected in the balance sheet per 31 December 2022.

The proposed amendment to the Investment Agreement, as well as the corresponding
amendments to the bond terms entered into with Nordic Trustee AS, and the
proposed share consolidation and share capital decrease, are subject to approval
by the general meeting. The Company's board of directors has resolved to summon
an extraordinary general meeting ("EGM") to be held at the Company's offices at
Lysaker on 27 September 2023 at 09:00 CET. The EGM notice is attached to this
announcement.

The proposed amendments to the Agreement have been published on the Company's
website: Extraordinary General Meeting
2023 (https://www.circio.com/en/extraordinary-general-meeting-september-2023/)
(Governance / General meetings) and is also attached to this announcement.

Attachements:

EGM notice Circio Holding ASA - with English
appendix.pdf (https://mb.cision.com/Public/17093/3830823/b426ca545f903664.pdf)

EGM notice Circio Holding ASA - with Norwegian
appendix.pdf (https://mb.cision.com/Public/17093/3830823/9490b1a2ac022d92.pdf)

Circio investment and subscription - Amendment
agreement.pdf (https://mb.cision.com/Public/17093/3830823/94c7b7b3a279748c.pdf)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel
circRNA medicines for cancer, vaccines, rare disease, protein replacement
therapy and cell therapy. The proprietary circVec technology is based on a
modular genetic cassette design for efficient biogenesis of multifunctional
circRNA that can be deployed for many purposes. The most advanced concept,
circAde, builds on the companyŽs validated adenovirus platform to deliver
circRNA for durable expression of therapeutic proteins directly into cancer
cells. This unique approach is the only currently known circRNA program capable
of targeting solid tumors. The circVec platform has broad potential
applications, and CircioŽs strategy is to generate one or more lead candidates
for in house development in specific disease indications and in parallel seek
partnerships for other technical applications and therapeutic areas. The circRNA
R&D activities are being conducted by the wholly owned subsidiary Circio AB
based at the Karolinska Institute in Stockholm, Sweden.

In addition to Circio's circRNA program, the Company's' clinical stage
immunotherapy programs are designed to activate the patientŽs own immune system
to fight cancer cells and provide benefit to patients with no or few treatment
alternatives. ONCOS-102 has demonstrated an excellent safety profile, strong
immune responses and clinical efficacy in several cancer types in Phase 1/2
studies, both as monotherapy and in combinations with checkpoint inhibitors or
standard-of-care chemotherapy. A phase 2 trial to confirm the therapeutic
activity of ONCOS-102 in melanoma patients resistant to PD-1 checkpoint
inhibitor treatment has been designed, and Circio is seeking external financing
and/or partnerships to continue the clinical development.

Circio's second clinical stage program is an immunotherapy targeting KRAS driver
mutations. TG01 has previously shown robust immune responses and encouraging
clinical benefit in surgically resected pancreatic cancer and is currently being
tested in two clinical trials in RAS-mutated pancreatic cancer and multiple
myeloma in the USA and Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating broad future optionality for
the TG01 program at low cost to Circio.